Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jan Witowski
AddedJun 26, 2026
UpdatedJun 26, 2026
Jan Witowski

Jan Witowski

Co-founder & CEO, Ataraxis AI

LinkedIn

Jan Witowski's Career

Ataraxis AI
Ataraxis AI

New York, NY, US

Co-founder & CEO

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jan Witowski's Career

Ataraxis AI
Ataraxis AI
Series A$20.4M2023New York, NY, US
Co-founder & CEO

Recent news

Ataraxis AI Launches Ataraxis Breast NEO, a New AI Test Predicting Response to Neoadjuvant Therapy in Breast CancerBusiness Wire · 2026
Ataraxis AI Launches Ataraxis Breast CTX, the First Predictive AI Test Estimating Individualized Chemotherapy Benefit in Breast CancerBusiness Wire · 2026
Ataraxis AI and Unicancer Partner to Validate Ataraxis Breast Prognostic Tool Using Global Phase III Trial DataBusiness Wire · 2026

Similar to Ataraxis AI

TempusTempusChicago, IL, USData Analysis, Genomic Sequencingest. 2015TempusChicago, IL, US · est. 2015

Chicago-based Tempus Labs, Inc. offers genomic sequencing and data analysis for real-time medical decisions in the US.

Late Stage Private · $1.3B2.4k
ArteraArteraLos Altos, CA, USCancer Testsest. 2021ArteraLos Altos, CA, US · est. 2021

Artera: Precision medicine provider using AI for personalized cancer treatments and risk analysis.

Series B · $110M175
Precision Health AIPrecision Health AINew York City, NY, USHealthcare, Oncologyest. 2016Precision Health AINew York City, NY, US · est. 2016

Precision Health AI: Leveraging AI for oncology, enhancing outcomes and value-based care.

Series A · $20M30
Slideflow LabsSlideflow LabsChicago, IL, USest. 2024Slideflow LabsChicago, IL, US · est. 2024

Slideflow Labs develops an AI platform for digital pathology that transforms H&E slides into quantitative cancer biomarkers.

Accelerator · $120k

People Similar to Jan Witowski

Fryderyk WiatrowskiFryderyk WiatrowskiCo-founder & CEO · ViktorJanak SunilJanak SunilFounder · SpecificWitold WitkowiczWitold WitkowiczCEO, ICEYE Poland · ICEYEMariusz LusiakMariusz LusiakCo-Founder · CredictiveMichael PoliMichael PoliCo-Founder & Chief AI Scientist · Radical NumericsIan WangIan WangFounder · Axis